TY - JOUR
T1 - Multi-omics profiling of chronic immune-mediated skin diseases
T2 - SKINERGY protocol and strategic evaluation
AU - Koster, N. G.
AU - van den Reek, J. M.P.A.
AU - The Next Generation ImmunoDermatology (NGID) consortium
AU - de Jong, E. M.G.J.
AU - van Beugen, S.
AU - van Laarhoven, A. I.M.
AU - Haeck, I.
AU - de Bruin-Weller, M.
AU - Schuttelaar, M. L.
AU - Horvath, B.
AU - Gostyński, A.
AU - Knulst, A.
AU - Vermeer, M. H.
AU - Nguyen, L.
AU - Gerbens, L.
AU - Spuls, P.
AU - Middelkamp-Hup, M. A.
AU - Exadaktylos, V.
AU - Niemeyer-van der Kolk, T.
AU - Schrader, A. R.
AU - Sluijmers, A. M.
AU - Versteeg, J.
AU - Arents, B. W.M.
AU - van Ee, I.
AU - van der Zon, J. L.A.G.
AU - de Leeuw, M.
AU - de Leeuw, T.
AU - van den Broek, P.
AU - Berkhof, C.
AU - Vellinga, D.
AU - Weidinger, S.
AU - Dubrac, S.
AU - Li, Y.
AU - van Steensel, M.
AU - Marchetti-Deschmann, M.
AU - Maurer, M.
AU - van der Zee, H.
AU - Damman, J.
AU - Hijnen, D. J.
AU - Wijk, F.
AU - Seyger, M. M.B.
AU - Röckmann, H.
AU - Balak, D. M.W.
AU - van Doorn, M. B.A.
AU - Rissmann, R.
AU - Vreeken, Rob
AU - Cuypers, Eva
AU - Lelieveldt, Boudewijn
AU - El Ghalbzouri, Abdoel
AU - Niehues, Hanna
AU - van den Berge, Fauve
N1 - Publisher Copyright:
© 2026 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2026/2/6
Y1 - 2026/2/6
N2 - Background: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: ‘SKIN disease profiling by an Exploratory, pRospective, biomarker study in dermatoloGY practice (SKINERGY)’ will be conducted as a multicentre, parallel-cohort, open-label, observational, longitudinal basket study. Objectives: Objectives include evaluation of disease-related characteristics in comparison to those of healthy volunteers and evaluation of biomarkers for disease stratification and (targeted) treatment response in patients in a real-world clinical setting. Additionally, differences and similarities in disease characteristics between diseases, changes over time, and profiles of responders versus non-responders will be evaluated. Methods: Patients with AD (N = 120), PSO (N = 160), HS (N = 80), CSU (N = 120) and CLE (N = 120) will be enrolled in groups of N ≤ 40 patients per treatment. Matched healthy volunteers (N = 120) and the MF cohort (N = 120) will serve as control groups. Assessments include blood sampling, skin punch biopsies, tape stripping, skin swabs, (multimodal) imaging, tele-health and patient- and physician-reported outcomes. This manuscript describes the study protocol prior to data collection and its strategic evaluation of multi-omics profiling. Patient advocacy groups co-defined the research agenda and contributed to study design and informed consent document development, ensuring alignment with patients' needs and real-world relevance. Results: SKINERGY will generate a machine learning-ready dataset with information about changes in various biomarkers over time, including histology, metabolomics, spatial proteomics, transcriptomics, lipidomics, microbiomics, imaging biomarkers, tele-health, patient-reported outcome measures (PROMs) and clinical parameters. Conclusion:Identified biomarker profiles within SKINERGY may guide targeted treatment selection, enhance targeted therapeutic response in clinical practice and improve understanding of disease pathology in chronic immune-mediated skin diseases.
AB - Background: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: ‘SKIN disease profiling by an Exploratory, pRospective, biomarker study in dermatoloGY practice (SKINERGY)’ will be conducted as a multicentre, parallel-cohort, open-label, observational, longitudinal basket study. Objectives: Objectives include evaluation of disease-related characteristics in comparison to those of healthy volunteers and evaluation of biomarkers for disease stratification and (targeted) treatment response in patients in a real-world clinical setting. Additionally, differences and similarities in disease characteristics between diseases, changes over time, and profiles of responders versus non-responders will be evaluated. Methods: Patients with AD (N = 120), PSO (N = 160), HS (N = 80), CSU (N = 120) and CLE (N = 120) will be enrolled in groups of N ≤ 40 patients per treatment. Matched healthy volunteers (N = 120) and the MF cohort (N = 120) will serve as control groups. Assessments include blood sampling, skin punch biopsies, tape stripping, skin swabs, (multimodal) imaging, tele-health and patient- and physician-reported outcomes. This manuscript describes the study protocol prior to data collection and its strategic evaluation of multi-omics profiling. Patient advocacy groups co-defined the research agenda and contributed to study design and informed consent document development, ensuring alignment with patients' needs and real-world relevance. Results: SKINERGY will generate a machine learning-ready dataset with information about changes in various biomarkers over time, including histology, metabolomics, spatial proteomics, transcriptomics, lipidomics, microbiomics, imaging biomarkers, tele-health, patient-reported outcome measures (PROMs) and clinical parameters. Conclusion:Identified biomarker profiles within SKINERGY may guide targeted treatment selection, enhance targeted therapeutic response in clinical practice and improve understanding of disease pathology in chronic immune-mediated skin diseases.
UR - https://www.scopus.com/pages/publications/105030246623
U2 - 10.1111/jdv.70311
DO - 10.1111/jdv.70311
M3 - Article
C2 - 41645921
AN - SCOPUS:105030246623
SN - 0926-9959
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
ER -
SDG 3 Good Health and Well-being